ABT-263 (Navitoclax)

Catalog No.S1001

ABT-263 (Navitoclax) Chemical Structure

Molecular Weight(MW): 974.61

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck.

    PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

  • PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

    PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    ABT-263 (Navitoclax) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    ABT-263 (Navitoclax) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NXX2UGdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3SOItKSzVyPUCuNFA3PjlizszN M3vXd3NCVkeHUh?=
MV-4-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXZTWM2OD1yLkCxOVg3KM7:TR?= M3v2bHNCVkeHUh?=
NKM-1 M3TUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH71RnhKSzVyPUCuNFE3QTlizszN NXvYc|J7W0GQR1XS
ML-2 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr2NWtKSzVyPUCuNFE6QDNizszN NWrjW2FTW0GQR1XS
BV-173 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D1fmlEPTB;MD6wNlMyPCEQvF2= M3;FNXNCVkeHUh?=
RS4-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEK1PFch|ryP M1P4NHNCVkeHUh?=
HL-60 NHrH[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj2TWM2OD1yLkCyPVA5KM7:TR?= M3XZXXNCVkeHUh?=
KY821 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLjTWM2OD1yLkCyPVc2KM7:TR?= M{\C[nNCVkeHUh?=
ECC10 NEXlZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrVXY9KSzVyPUCuNFM4QTJizszN MoT5V2FPT0WU
NCI-H720 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK3TWM2OD1yLkC0NFEyKM7:TR?= MmrDV2FPT0WU
QIMR-WIL NUH1[FczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W1PGlEPTB;MD6wOFI5PyEQvF2= NILoPXNUSU6JRWK=
KG-1 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3hR2ZKSzVyPUCuNFQ1QDZizszN NH\TNoFUSU6JRWK=
TGW MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\XTHM3UUN3ME2wMlA1PjN|IN88US=> M2PafXNCVkeHUh?=
ATN-1 NX32ZWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;yZWlEPTB;MD6wOFc{OyEQvF2= NIH3V2hUSU6JRWK=
RH-18 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjSWG94UUN3ME2wMlA3ODR6IN88US=> M3nm[3NCVkeHUh?=
EW-18 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi4TWM2OD1yLkC2PFQyKM7:TR?= MonYV2FPT0WU
NB17 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEexNlQh|ryP M4\DbnNCVkeHUh?=
SK-NEP-1 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37OVmlEPTB;MD6wO|IyOyEQvF2= MnrsV2FPT0WU
P12-ICHIKAWA NXrTWXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M370[2lEPTB;MD6wO|c4QCEQvF2= Ml;nV2FPT0WU
KARPAS-45 NV35OmpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPrcWFKSzVyPUCuNFc5OTVizszN NIKzO45USU6JRWK=
EW-3 NX\2[3FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD3dHpxUUN3ME2wMlA5ODV|IN88US=> NG[4ZmlUSU6JRWK=
NB13 M3TKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\DbmlEPTB;MD6wPFIxOyEQvF2= NVXOWHdkW0GQR1XS
NCI-H209 Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEi3NFQh|ryP MWPTRW5ITVJ?
NCI-H1092 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW4cpBKSzVyPUCuNVAzPzVizszN MX7TRW5ITVJ?
NH-12 NIjj[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXudnhKSzVyPUCuNVA4PDRizszN NVf1Z|J[W0GQR1XS
697 NIC4[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7TTWM2OD1yLkGwPFM6KM7:TR?= Mk\SV2FPT0WU
KE-37 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO5cVBKSzVyPUCuNVE{PyEQvF2= NFX3PHRUSU6JRWK=
MOLT-4 M3vyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P2VGlEPTB;MD6xOVE3QSEQvF2= NXHQOlFqW0GQR1XS
CHP-134 NVjhZXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[3[2lEPTB;MD6xOlMxPiEQvF2= MmrIV2FPT0WU
D-283MED MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65SJZKSzVyPUCuNVc3QDZizszN MV3TRW5ITVJ?
LU-135 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XqVGlEPTB;MD6xPFU2OiEQvF2= MVjTRW5ITVJ?
LU-134-A NYDCU5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfj[ZdKSzVyPUCuNVg3PzFizszN MWfTRW5ITVJ?
EM-2 NIXLNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvpS3FKSzVyPUCuNVk6OThizszN NGnMemlUSU6JRWK=
LU-139 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HySmlEPTB;MD6yNFQ6QCEQvF2= MXzTRW5ITVJ?
ALL-PO NXnoSY5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TXUGlEPTB;MD6yNVk5QCEQvF2= MlzQV2FPT0WU
NB12 M4TTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HVdWlEPTB;MD6yN|EyPSEQvF2= NXPDUGRiW0GQR1XS
KP-N-YN MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u3TWlEPTB;MD6yN|U4OyEQvF2= NH\RWItUSU6JRWK=
BEN M4XhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r2ZmlEPTB;MD6yN|k3QCEQvF2= NV\NR|NVW0GQR1XS
HCC1569 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOwdlVuUUN3ME2wMlI2OTB4IN88US=> Mn3yV2FPT0WU
HuO9 NGLh[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPoNpNKSzVyPUCuNlY4OTVizszN MWHTRW5ITVJ?
WM-115 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSycFZEUUN3ME2wMlI4PzN6IN88US=> MV;TRW5ITVJ?
CCRF-CEM NIHVWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DnS2lEPTB;MD6zN|UzQSEQvF2= M3LZbHNCVkeHUh?=
IST-SL1 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfCT|Y1UUN3ME2wMlM2OzR|IN88US=> MmfpV2FPT0WU
BE-13 M2LNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwM{[0OVkh|ryP M1fYR3NCVkeHUh?=
COR-L88 M{DUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXrTWM2OD1yLkO2OVQh|ryP M{\ONXNCVkeHUh?=
DOHH-2 M2DRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HJbGlEPTB;MD60NVAzOyEQvF2= NXfLWmRLW0GQR1XS
A704 M{f0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwNEK2O{DPxE1? NGPONZVUSU6JRWK=
KNS-81-FD MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGwb|VKSzVyPUCuOFQxOTdizszN NFHoRmVUSU6JRWK=
RPMI-8226 M3fRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\T[mJtUUN3ME2wMlQ2PjV{IN88US=> NGrRfGFUSU6JRWK=
TGBC24TKB M2nHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCzTWM2OD1yLkS1O|c5KM7:TR?= M{TQfHNCVkeHUh?=
NCI-H1304 NHrSUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojFTWM2OD1yLkS2NVU4KM7:TR?= M322dHNCVkeHUh?=
MOLT-13 M3XDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXtUo1MUUN3ME2wMlQ3PjF|IN88US=> NIPaNGRUSU6JRWK=
EW-22 NX7DPXNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\xXINKSzVyPUCuOFY3PzFizszN M3TmZXNCVkeHUh?=
MS-1 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XUTGlEPTB;MD60Olk{OyEQvF2= NYW0OW9CW0GQR1XS
RMG-I NHTxOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwNEm0OlQh|ryP M1[0XHNCVkeHUh?=
NTERA-S-cl-D1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV23NI9WUUN3ME2wMlUxODF7IN88US=> NEW2NYNUSU6JRWK=
NCI-H1048 NGiycVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PhVWlEPTB;MD61NFk2OyEQvF2= NWC3WXV2W0GQR1XS
SW1417 NGPhOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNUW0N|gh|ryP NXPwdHB1W0GQR1XS
DB MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\UVGlEPTB;MD61O|A5KM7:TR?= NX7We|FRW0GQR1XS
MEG-01 M1\5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXXfI5uUUN3ME2wMlU5OzJizszN MnmzV2FPT0WU
EW-13 M3rrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwNUizOFEh|ryP M1TEeHNCVkeHUh?=
LAMA-84 M1q0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf3V|NSUUN3ME2wMlU6OjB5IN88US=> MoPXV2FPT0WU
J-RT3-T3-5 NGnRdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0cGlEPTB;MD62NFgxQCEQvF2= MUjTRW5ITVJ?
MOLT-16 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy4c29NUUN3ME2wMlY2OjZ2IN88US=> MV;TRW5ITVJ?
DU-4475 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfMcHhCUUN3ME2wMlY2PDJ5IN88US=> NGi0N2dUSU6JRWK=
HAL-01 NF\BO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK2TWM2OD1yLkeyOVQ6KM7:TR?= MYPTRW5ITVJ?
RD MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPKXINKSzVyPUCuO|U5QTlizszN NFO2dWJUSU6JRWK=
OAW-28 M1G3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HZ[2lEPTB;MD63PFM4KM7:TR?= MYLTRW5ITVJ?
HCC38 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPW[plKSzVyPUCuPFAyQSEQvF2= MlTuV2FPT0WU
NMC-G1 NXzhN5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwOEGxNlEh|ryP NIXEV2tUSU6JRWK=
EW-16 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHpRlJ[UUN3ME2wMlgyOzJ6IN88US=> M336dXNCVkeHUh?=
DU-145 NEn3dJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPETWM2OD1yLki5PVI{KM7:TR?= NWLldWE2W0GQR1XS
HPAF-II NHjIRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTaTWM2OD1yLkmyOlI5KM7:TR?= MnrkV2FPT0WU
A427 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwOUOwNlIh|ryP MlrwV2FPT0WU
PA-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXFeWNmUUN3ME2wMlk2PjR{IN88US=> MlPhV2FPT0WU
OAW-42 NIn0[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvTWM2OD1yLkm2NVQ3KM7:TR?= Ml\nV2FPT0WU
L-428 NF73dJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Ljc2lEPTB;MT6wNVI2KM7:TR?= NFLaU3RUSU6JRWK=
COLO-824 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwMEG3NFgh|ryP NHXmRVNUSU6JRWK=
P30-OHK NUO1TmNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkiwTWM2OD1zLkC0Olg5KM7:TR?= NWjueIQyW0GQR1XS
NCI-H2170 NFLQNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPPcpZHUUN3ME2xMlA3OjNizszN NYTLWIJ2W0GQR1XS
HCC2998 NVLkWmM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwMEexN|Uh|ryP M{HlOXNCVkeHUh?=
NB14 MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\yN|dKSzVyPUGuNVM4PDhizszN MYXTRW5ITVJ?
TGBC1TKB M1njWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwMUSxOVIh|ryP NVrsXFV5W0GQR1XS
KP-N-YS NHqyeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfwO5hKSzVyPUGuNVYzOzZizszN MV;TRW5ITVJ?
CAL-120 M2L0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMU[0Nlkh|ryP M4XGSHNCVkeHUh?=
SBC-1 NWfpWFNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jzW2lEPTB;MT6xPVA2OyEQvF2= NF\MRZlUSU6JRWK=
C32 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDQWFVKSzVyPUGuNVkxQDhizszN MoLDV2FPT0WU
HCC2157 M3rwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3a[WpKSzVyPUGuNVk1QTRizszN NGeyeG5USU6JRWK=
COLO-792 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPZcnFKSzVyPUGuNlAxPzFizszN NFTUcZVUSU6JRWK=
ES7 NWHyUndoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMke5OVEh|ryP MmTwV2FPT0WU
HEL Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P1OWlEPTB;MT6zNVAzQSEQvF2= NFvvS2JUSU6JRWK=
ES4 NEKyUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwM{S5PVgh|ryP NHLROHJUSU6JRWK=
NCI-SNU-1 M13pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjJWGJKSzVyPUGuN|Y2PTVizszN MYPTRW5ITVJ?
MDA-MB-415 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\3SWlEPTB;MT6zPFg2KM7:TR?= MlTXV2FPT0WU
NCI-H2342 M37YR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP5W|FKSzVyPUGuOFAzPjlizszN NFXEV|NUSU6JRWK=
NB69 MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\IWmlEPTB;MT60OlI4OSEQvF2= NFP3VVdUSU6JRWK=
D-247MG MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i2OGlEPTB;MT61NVEzOiEQvF2= NXjoR|BHW0GQR1XS
SCC-4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e4emlEPTB;MT61PVg5PyEQvF2= NGDVVZhUSU6JRWK=
HuH-7 NXO0R2I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;TO5A4UUN3ME2xMlY4Ojl|IN88US=> NHrwRlhUSU6JRWK=
A388 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn1TWM2OD1zLk[4O|I1KM7:TR?= NUPadVQ2W0GQR1XS
Calu-3 M2HiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXqTWM2OD1zLkewOlk4KM7:TR?= MXfTRW5ITVJ?
NCI-H1648 M4PiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M123UmlEPTB;MT63NVQyQCEQvF2= NGjiemlUSU6JRWK=
NCI-H2052 NHHWPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXzdlRXUUN3ME2xMlczOjBzIN88US=> NFHkVZhUSU6JRWK=
Ramos-2G6-4C10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;DclMyUUN3ME2xMlc{PjV4IN88US=> MlrmV2FPT0WU
DEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XWcWlEPTB;MT63OFY6OiEQvF2= NEPQbJNUSU6JRWK=
SNU-423 M3fvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG4NphKSzVyPUGuO|gyPTdizszN M1KwTXNCVkeHUh?=
COR-L23 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TpUGlEPTB;MT63PVg4PCEQvF2= MY\TRW5ITVJ?
OMC-1 NVW0SnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjD[mJKSzVyPUGuPFYxOTZizszN NGP6U|hUSU6JRWK=
EW-11 M3Lwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi5T5FuUUN3ME2xMlk2PjV5IN88US=> M4Hsc3NCVkeHUh?=
HSC-3 NIXBXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7TTWM2OD1zLkm2N|Y2KM7:TR?= NVvmfYhNW0GQR1XS
MLMA NYm0Ulh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwOU[2O|ch|ryP NYjSeXZwW0GQR1XS
RCM-1 NV7rN29rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF73XJRKSzVyPUKuNFA{QTlizszN NWfqUYI5W0GQR1XS
MFE-280 NIHoe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvuTWM2OD1{LkCyPFQ5KM7:TR?= NXfXTnNMW0GQR1XS
ES8 NWP4bpFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P3[2lEPTB;Mj6yOVQ4OSEQvF2= NFTuZ4hUSU6JRWK=
TE-11 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn5NYR4UUN3ME2yMlI6PDd|IN88US=> Mnr0V2FPT0WU
HuO-3N1 NYqzclQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLaRnFKSzVyPUKuOFg4QCEQvF2= MknZV2FPT0WU
MHH-NB-11 NVHibVc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwNUGxOVgh|ryP M37qeXNCVkeHUh?=
TGBC11TKB M3zJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHCOJpKSzVyPUKuOVc3QDFizszN NVj4dWUyW0GQR1XS
HOP-92 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fobGlEPTB;Mj61PFc1OyEQvF2= MnK1V2FPT0WU
IGR-1 NHPT[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETtbZFKSzVyPUKuOlIxOzVizszN MXPTRW5ITVJ?
GOTO M3PzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zLfmlEPTB;Mj62OVM4PyEQvF2= MYHTRW5ITVJ?
NCI-H1650 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LkfWlEPTB;Mj63NlIyPSEQvF2= NFnXc45USU6JRWK=
NCI-H1581 M4PrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljyTWM2OD1{Lke5OlgyKM7:TR?= MYfTRW5ITVJ?
NCI-H2405 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7LTWM2OD1{LkiyO|gzKM7:TR?= M2rBcHNCVkeHUh?=
U-118-MG M1\mbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzVTWM2OD1{Lkm2OFkyKM7:TR?= NX:5RlBsW0GQR1XS
DoTc2-4510 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXlWJc3UUN3ME2zMlAyPDF5IN88US=> Mn3BV2FPT0WU
NCI-H596 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlruTWM2OD1|LkC0PVk4KM7:TR?= M3Hs[HNCVkeHUh?=
MPP-89 NHjWZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr0Wm9pUUN3ME2zMlA2PjZ4IN88US=> Mo[zV2FPT0WU
GCIY NHm1XXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqwTWM2OD1|LkKwOFkyKM7:TR?= NYHpemhSW0GQR1XS
SW626 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNwMkS1OFMh|ryP MkDCV2FPT0WU
OCI-AML2 M{XZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNwM{GyO|Ih|ryP NXrEOGN7W0GQR1XS
NBsusSR NX7E[mhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDmTWM2OD1|LkO0PVM5KM7:TR?= MUDTRW5ITVJ?
AN3-CA M36xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfBVmpyUUN3ME2zMlQ1OjN6IN88US=> M2LscHNCVkeHUh?=
EFM-19 NHG2dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HyVGlEPTB;Mz60PFM{QSEQvF2= MXPTRW5ITVJ?
RVH-421 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TjRmlEPTB;Mz61Olg4PyEQvF2= MoLTV2FPT0WU
5637 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnPTWM2OD1|Lk[xNVA{KM7:TR?= MWjTRW5ITVJ?
PANC-08-13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPhPXZ6UUN3ME2zMlY{PDd{IN88US=> MoW4V2FPT0WU
H9 NF\ZdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7HfXNMUUN3ME2zMlY4OTR2IN88US=> MVfTRW5ITVJ?
KARPAS-299 M3v4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n3V2lEPTB;Mz62O|M3OSEQvF2= Ml\hV2FPT0WU
TE-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTWbXdKSzVyPUOuO|A4ODlizszN NXnQfnE3W0GQR1XS
NOS-1 NWjOWG1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnDTWM2OD1|Lke5PFM1KM7:TR?= NV;nSIU1W0GQR1XS
HH NYHaSpBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPQ[4JPUUN3ME2zMlg{QDZ6IN88US=> M3HqVHNCVkeHUh?=
769-P MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TTXWlEPTB;Mz64PVUyKM7:TR?= NWDVdlY4W0GQR1XS
CHP-212 NEPkcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNwOUK1OFkh|ryP MYTTRW5ITVJ?
NCI-H82 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPwd2NKSzVyPUOuPVU6OzZizszN NVvwdWVGW0GQR1XS
Mo-T Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fWVmlEPTB;ND6wOFMyOiEQvF2= MkDLV2FPT0WU
BB65-RCC NUHtVnRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvoTWM2OD12LkC0N|k6KM7:TR?= NXiwXZZHW0GQR1XS
SW1990 M4TySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRwMEW5NFgh|ryP MlG2V2FPT0WU
LK-2 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrNXmRKSzVyPUSuNVEzQTNizszN M{X2SHNCVkeHUh?=
ES5 NWXsO4pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nRe2lEPTB;ND6xN|k5PSEQvF2= MkC1V2FPT0WU
JVM-3 NWfwZZV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTRwMUiyNlIh|ryP NYTTTo1oW0GQR1XS
RPMI-7951 NFXienlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi1SHZKSzVyPUSuNlI1OTNizszN MlO5V2FPT0WU
Calu-6 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRwMke4PFEh|ryP MljPV2FPT0WU
LC-2-ad Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLpTWM2OD12LkK5OVY5KM7:TR?= MWDTRW5ITVJ?
SW954 NXzKOolmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX1TWM2OD12LkK5OlYh|ryP MnTRV2FPT0WU
H-EMC-SS NVjMbYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXlVXdKSzVyPUSuN|E5OzFizszN NXnsO3lzW0GQR1XS
ES3 M{\Qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrXOJNXUUN3ME20MlM2PDRzIN88US=> MnzoV2FPT0WU
no-11 NXrz[VlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3izZWlEPTB;ND6zOVU2PCEQvF2= MWnTRW5ITVJ?
LAN-6 M1vkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXERpBwUUN3ME20MlQ2OTh7IN88US=> NH7BVldUSU6JRWK=
FTC-133 NF;jW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjOfpc1UUN3ME20MlU{QTVizszN NEDpSGNUSU6JRWK=
8505C MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjxTWM2OD12LkW0NlMh|ryP M2r0dHNCVkeHUh?=
SW620 NW\CUVI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRwNUewOVch|ryP MULTRW5ITVJ?
BCPAP MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz4PY1KSzVyPUSuOlM1QDFizszN M4eyenNCVkeHUh?=
SK-LU-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTRwNk[wPFkh|ryP NEjvZWhUSU6JRWK=
NCI-H1623 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTRwN{CyNlgh|ryP MljDV2FPT0WU
C2BBe1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vjVmlEPTB;ND63OFAxQCEQvF2= MWTTRW5ITVJ?
GP5d NFznRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRwN{izPFgh|ryP MUHTRW5ITVJ?
NB6 NX3Ze5hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC3NYdHUUN3ME20Mlg3OjB2IN88US=> NV\4VZduW0GQR1XS
MDA-MB-157 NHjyTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m2RmlEPTB;ND64PFc3KM7:TR?= MWTTRW5ITVJ?
UMC-11 NYDaTZAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL2U|FKSzVyPUSuPFg6PjRizszN NHLv[oVUSU6JRWK=
HCC1419 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXoTWM2OD12LkmwNFY{KM7:TR?= MoL4V2FPT0WU
NCI-H2029 M2PlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\lTWM2OD12Lkm0NVg2KM7:TR?= NVzHNotlW0GQR1XS
LXF-289 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGzUmRKSzVyPUWuNFM4OTlizszN NVn2T|Z7W0GQR1XS
KINGS-1 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVwMEe3OFQh|ryP NXHaWFJEW0GQR1XS
HD-MY-Z MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\GbGp3UUN3ME21MlI{QTZ7IN88US=> MXLTRW5ITVJ?
ESS-1 NFXNWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3QZVltUUN3ME21MlI2PTl5IN88US=> M3P4VnNCVkeHUh?=
GI-1 NVrwfJA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT4TWM2OD13LkK3PVI3KM7:TR?= M{\m[XNCVkeHUh?=
RPMI-2650 NU\LdYtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6c4hKSzVyPUWuN|YyPiEQvF2= MnfOV2FPT0WU
IA-LM MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f4eGlEPTB;NT6zPVg4OSEQvF2= NEXxdIRUSU6JRWK=
KP-4 NFLhO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTVwNE[zN|Qh|ryP NUfuV3R3W0GQR1XS
G-402 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3WSm5KSzVyPUWuOVE5PjVizszN MYPTRW5ITVJ?
OS-RC-2 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwNUK2NFQh|ryP M1zYO3NCVkeHUh?=
NCI-H1155 NHX4eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjNWW95UUN3ME21MlU1QTV3IN88US=> NWHyT5FNW0GQR1XS
OE19 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXyWFhKSzVyPUWuOlg3OjRizszN NVjPdVNuW0GQR1XS
U-2-OS MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXxNm5KSzVyPUWuPFkxOTNizszN M3zGS3NCVkeHUh?=
SCC-15 NHL2[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTsN4RKSzVyPUWuPVM3PjJizszN MUnTRW5ITVJ?
NCI-H630 NHT0fohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K4bmlEPTB;NT65PVQxPCEQvF2= NFXKXFdUSU6JRWK=
PFSK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHkTWM2OD14LkC1NlU6KM7:TR?= M1rYN3NCVkeHUh?=
NCI-H1770 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwMkC4O|Qh|ryP MWrTRW5ITVJ?
SK-MEL-3 M3XBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLBTWM2OD14LkSyPVE2KM7:TR?= MVjTRW5ITVJ?
LB1047-RCC M13aOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OyO2lEPTB;Nj60O|YzPSEQvF2= Ml:2V2FPT0WU
NCI-H446 NGm2TJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rTcGlEPTB;Nj62NlkzPSEQvF2= NGXh[YdUSU6JRWK=
SW780 NHf1bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnjTWM2OD14LkewNVg2KM7:TR?= NVvGTGs2W0GQR1XS
NEC8 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe3XItKSzVyPU[uO|Y3OyEQvF2= Mlr6V2FPT0WU
NOMO-1 NH3heVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXhTWM2OD14Lke4NVEyKM7:TR?= NFHDV4hUSU6JRWK=
COLO-668 Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLHVJBKSzVyPU[uPFQ{QDdizszN MVPTRW5ITVJ?
MC116 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTZwOUO4PVch|ryP NUP6T5BpW0GQR1XS
HCC1937 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;i[JZKSzVyPU[uPVkzPTFizszN NULQc4VGW0GQR1XS
NCI-N87 NEf6dWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PXT2lEPTB;Nz6xPVI6OyEQvF2= MmDNV2FPT0WU
COLO-320-HSR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hrc2lEPTB;Nz6yNlc{QCEQvF2= MV;TRW5ITVJ?
HCC1806 M{TrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W1O2lEPTB;Nz6yOlA1PCEQvF2= NWLafFJOW0GQR1XS
OVCAR-3 NHT1colIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;hdmlEPTB;Nz6zN|A{QCEQvF2= MYPTRW5ITVJ?
NUGC-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTWTWM2OD15LkO5Olk1KM7:TR?= MXnTRW5ITVJ?
SW1783 M1fnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jVS2lEPTB;Nz60N|E4PSEQvF2= M2fSSHNCVkeHUh?=
GCT NGjsdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M176cmlEPTB;Nz61OlkxPiEQvF2= MnO2V2FPT0WU
NCI-H2126 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTdwN{O2NlUh|ryP NIrkOHFUSU6JRWK=
MEL-HO MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPCbHlXUUN3ME23Mlc4ODV2IN88US=> NXvNR2wyW0GQR1XS
CAPAN-1 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHNT3ZKSzVyPUeuO|c{PTdizszN MUXTRW5ITVJ?
SW756 M17IUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XkfWlEPTB;Nz63PFM{OyEQvF2= MVXTRW5ITVJ?
SKG-IIIa M{ewUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEewU3pKSzVyPUeuPFE5QTJizszN NWfKNIprW0GQR1XS
HCE-T NUW0fVg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[zSmlEPTB;Nz64O|c5OyEQvF2= MVrTRW5ITVJ?
Ca-Ski M4H3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ftSWlEPTB;Nz65PVM5OyEQvF2= MXTTRW5ITVJ?
COLO-684 NXX6dld[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG5TWM2OD16LkCxPFE5KM7:TR?= MUTTRW5ITVJ?
KYSE-70 M4m0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThwMEe3Nlkh|ryP NELHT5lUSU6JRWK=
TI-73 NIThb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT4TWM2OD16LkK1PFUyKM7:TR?= NHLsXJFUSU6JRWK=
BT-20 NY\1UXdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG4W|ZKSzVyPUiuNlYxPTJizszN NIrYT3FUSU6JRWK=
MHH-ES-1 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m0[mlEPTB;OD61NVg{PCEQvF2= MnPDV2FPT0WU
TE-12 NWniTnRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj6No5KSzVyPUiuOVk6OzFizszN NYjvOodDW0GQR1XS
YH-13 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPEVYdKSzVyPUiuOlExODhizszN NUTYS4dZW0GQR1XS
SF126 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m5UmlEPTB;OD64N|g3PSEQvF2= NWTiO2Y5W0GQR1XS
J82 MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq4TWM2OD16LkmwNFM5KM7:TR?= M2nyfnNCVkeHUh?=
RCC10RGB NVfkbYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn5b5A4UUN3ME24Mlk6PTZzIN88US=> NUH5RWxTW0GQR1XS
SK-UT-1 NWXIfmJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPBd3c1UUN3ME25MlA1QTR3IN88US=> MU\TRW5ITVJ?
LB2241-RCC NGDFS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD5TWM2OD17LkG5NVM4KM7:TR?= NUfMXFlXW0GQR1XS
LB996-RCC NIq0OpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTlwMUm4PUDPxE1? MkTPV2FPT0WU
EPLC-272H Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfkTWM2OD17LkO3OlU4KM7:TR?= NGjnN3dUSU6JRWK=
CTV-1 NXzkN4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn35TWM2OD17LkW2OVMzKM7:TR?= NVHucXQxW0GQR1XS
HSC-2 NUPrcYhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37idWlEPTB;OT61O|U2KM7:TR?= M3TTdnNCVkeHUh?=
SK-MEL-28 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfQNXhKSzVyPUmuOlE5QTNizszN NWDJVG8xW0GQR1XS
MMAC-SF MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfGd45KUUN3ME25MlY5PzVizszN NEjFNVNUSU6JRWK=
CP50-MEL-B Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTlwN{W3PFIh|ryP Mn;mV2FPT0WU
HT-1080 M4jYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nwRWlEPTB;OT63O|c{QSEQvF2= MVLTRW5ITVJ?
HEC-1 NYTHdIRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS5dlVKSzVyPUGwMlM{PTJizszN NFLYUHJUSU6JRWK=
AGS NEHtUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\GOpBKSzVyPUGwMlM4PCEQvF2= NIDWSnBUSU6JRWK=
GAMG M4LOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK1TWM2OD1zMD61NVYzKM7:TR?= NXzHVI1UW0GQR1XS
SW48 NWGwWYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFyLkWxPFkh|ryP NFGyW3RUSU6JRWK=
U031 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7MTWM2OD1zMD61PVA5KM7:TR?= M1vPeXNCVkeHUh?=
OVCAR-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTtTWM2OD1zMD62OFI6KM7:TR?= MlHGV2FPT0WU
SF295 NH3OcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFyLk[3NFQh|ryP NFK1clhUSU6JRWK=
BHT-101 NEHwPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFyLkexO|ch|ryP M4XmfnNCVkeHUh?=
VMRC-RCZ MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFzLkOyNFEh|ryP Ml\6V2FPT0WU
ACHN NV73NINvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDuTWM2OD1zMT60NlEyKM7:TR?= MWDTRW5ITVJ?
NCI-H526 M2LkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHqT4pKSzVyPUGxMlUxPDNizszN MYnTRW5ITVJ?
MN-60 M13PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33FRmlEPTB;MUGuOVM6KM7:TR?= M1PROHNCVkeHUh?=
NCI-H2291 NUXw[I9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmzTWM2OD1zMT61OFY3KM7:TR?= NFfIT2VUSU6JRWK=
SCC-25 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO5[HhKSzVyPUGxMlc2PTZizszN NEjsXm5USU6JRWK=
SK-MEL-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDJWVRxUUN3ME2xNU44PjN5IN88US=> NGjxN5JUSU6JRWK=
SN12C MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrKOYlYUUN3ME2xNU46OzV3IN88US=> NGCzOZRUSU6JRWK=
NCI-H69 MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzPTWM2OD1zMj60NlM1KM7:TR?= Mn[zV2FPT0WU
ME-180 NUjvVW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF{LkewOVQh|ryP NXf6fo9SW0GQR1XS
MC-IXC M1e2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTkeXZKSzVyPUGyMlc2OThizszN MYLTRW5ITVJ?
NCI-H2347 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHITWM2OD1zMj63OlE1KM7:TR?= MUXTRW5ITVJ?
M059J NEe5[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF{Lke3Nlch|ryP M4jhTnNCVkeHUh?=
A2058 NELDd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF{Lki2PFEh|ryP M1zhUXNCVkeHUh?=
VA-ES-BJ NVjkWG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LUeGlEPTB;MUKuPFc5PSEQvF2= NGLyeJRUSU6JRWK=
Ca9-22 M1;uO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPZbo9KSzVyPUGyMlk1PTFizszN M{PHcXNCVkeHUh?=
KNS-42 NEWzSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3oTWM2OD1zMj65PVg1KM7:TR?= M4rM[XNCVkeHUh?=
LoVo M4W0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXSTWM2OD1zMz6yN|E{KM7:TR?= MVrTRW5ITVJ?
AM-38 NGq1ZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTLVWhXUUN3ME2xN{4zPTZ4IN88US=> NIj1eXZUSU6JRWK=
NB5 M{jKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF|LkO3OVIh|ryP MmnRV2FPT0WU
L-363 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLnTWM2OD1zMz60NFM{KM7:TR?= MoDiV2FPT0WU
SK-MEL-30 NXnDU4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3wSI5KSzVyPUG0MlA3PDVizszN NX\1PIlDW0GQR1XS
NCI-H1563 NGTiS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPtXFRKSzVyPUG0MlYxOzlizszN M2fHXHNCVkeHUh?=
NCI-H2228 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF2Lk[wO|ch|ryP M3XGN3NCVkeHUh?=
MFM-223 M2X5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF3LkG4NVMh|ryP MmHRV2FPT0WU
LB831-BLC NHrWU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;KTHVKSzVyPUG1MlI4PjdizszN NGLFd2pUSU6JRWK=
SW872 NIP4ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HvW2lEPTB;MUWuN|A5PiEQvF2= MV;TRW5ITVJ?
NCI-H522 NH6wOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\zWm5KSzVyPUG1MlM{ODZizszN MY\TRW5ITVJ?
EW-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnHTWM2OD1zNT61OFYzKM7:TR?= MoPDV2FPT0WU
HN NFLtfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF3LkW5OFIh|ryP NVvWZ4tqW0GQR1XS
SW837 NVf5NYN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPBUoNKSzVyPUG1Mlc5PDdizszN NEDUVYlUSU6JRWK=
SCC-9 M4\RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF3LkixNVQh|ryP NYDpNHV6W0GQR1XS
MKN7 NIe2UI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq4e3BIUUN3ME2xOU46PzN{IN88US=> NH3Tc2pUSU6JRWK=
KYSE-410 NXvl[2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLNTWM2OD1zNj61PVEh|ryP M2m1U3NCVkeHUh?=
SK-N-DZ NFSyXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF4Lk[xNVYh|ryP MknTV2FPT0WU
COR-L105 M1XCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLBTWM2OD1zNj62OVI5KM7:TR?= M3XuXHNCVkeHUh?=
LB2518-MEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXONpNKSzVyPUG2Mlg{QDlizszN NF\BUG1USU6JRWK=
OVCAR-4 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHQPVlKSzVyPUG2Mlg5PjJizszN NGrsTJhUSU6JRWK=
TK10 NV\ybZRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiwcW1qUUN3ME2xOk46PDd|IN88US=> M4fLZnNCVkeHUh?=
KNS-62 M{DMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF4Lkm3O|ch|ryP NWfDbYFkW0GQR1XS
RPMI-8866 NFvuWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3LZppRUUN3ME2xO{4yPzN{IN88US=> NH3RSpBUSU6JRWK=
HuP-T4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW3VG1KSzVyPUG3MlI1QTVizszN M3LwVnNCVkeHUh?=
CGTH-W-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfYZmlKSzVyPUG3MlUzOTlizszN NV7PXlFyW0GQR1XS
T-24 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LSRWlEPTB;MUeuOVM1PyEQvF2= NVPJcXNnW0GQR1XS
HT-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\S[2lEPTB;MUeuOVkyPCEQvF2= MYPTRW5ITVJ?
KS-1 NWO2PINtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;sN29KSzVyPUG3MlY4OyEQvF2= NGLCNFNUSU6JRWK=
NCI-H1792 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojCTWM2OD1zNz63PVgh|ryP M{LX[nNCVkeHUh?=
ABC-1 NFXoe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF5LkixOFEh|ryP M{DofXNCVkeHUh?=
BPH-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF6LkG2PFUh|ryP NHThZoRUSU6JRWK=
A431 M3nJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fDcGlEPTB;MUiuOFEzPyEQvF2= MXvTRW5ITVJ?
T98G NUfk[Hk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TtPWlEPTB;MUiuOVE2PyEQvF2= M2rGbXNCVkeHUh?=
BHY NV;GUYR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HxTmlEPTB;MUiuPFY6KM7:TR?= NXm5S3NLW0GQR1XS
Capan-2 M4Dx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nXS2lEPTB;MUiuPVA4QCEQvF2= NVm3Zll7W0GQR1XS
MDA-MB-175-VII MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrPRYFKSzVyPUG4MlkzODlizszN MVPTRW5ITVJ?
CAL-27 NYHOZphOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULpSXJmUUN3ME2xPU4xPDh5IN88US=> NEDoPJVUSU6JRWK=
AsPC-1 NEf3[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL6fmJKSzVyPUG5Mlg3PTdizszN NV7uTpR3W0GQR1XS
KU812 M1\sPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDTR2Y{UUN3ME2xPU46PTd|IN88US=> M{jCeHNCVkeHUh?=
NCI-H441 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTOTWM2OD1{MD6wNFEh|ryP MniyV2FPT0WU
Mewo M4LkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJyLkGyPFgh|ryP M3j1UXNCVkeHUh?=
SK-MEL-24 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXNGlEPTB;MkCuNVQ4PyEQvF2= M1fuU3NCVkeHUh?=
NCI-H727 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrhTWM2OD1{MD6yO|A1KM7:TR?= MVTTRW5ITVJ?
EKVX NUPLcXJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TTfWlEPTB;MkCuOlA3KM7:TR?= MXfTRW5ITVJ?
RT-112 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjmNmNjUUN3ME2yNE43OTJ{IN88US=> NFHqfoZUSU6JRWK=
CAMA-1 NUPwfFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTFTWM2OD1{MD65PFA{KM7:TR?= M1nlVXNCVkeHUh?=
SW900 NUTH[G1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJzLkCxOFkh|ryP NX7teYV7W0GQR1XS
NCI-H23 Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PVcmlEPTB;MkGuNVI4PyEQvF2= NV3aRVFxW0GQR1XS
SK-PN-DW Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlKxTWM2OD1{MT6xOlQ6KM7:TR?= NXPNOllNW0GQR1XS
BB30-HNC M{fjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3uPFNoUUN3ME2yNU4zPzR3IN88US=> NHjhfIFUSU6JRWK=
VM-CUB-1 M{TKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfLe4s3UUN3ME2yNU4{PTN4IN88US=> NUm0[IxQW0GQR1XS
IST-MEL1 M1PoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\IbYpYUUN3ME2yNU4{Pjl{IN88US=> MWHTRW5ITVJ?
CTB-1 NW\kcnczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12zN2lEPTB;MkGuOFc2PSEQvF2= NVHuWVQ{W0GQR1XS
LCLC-103H NUG3UlB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi0PJVrUUN3ME2yNk4yPTh{IN88US=> NYS5SZFQW0GQR1XS
PANC-03-27 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ{LkWxOlkh|ryP NHz0[XpUSU6JRWK=
HTC-C3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ{LkW1OVUh|ryP MUjTRW5ITVJ?
TE-8 NX;4dos4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\FXFZqUUN3ME2yN{4zPTZ3IN88US=> NYG1c|lEW0GQR1XS
NCI-H292 M33Gbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;ZS2lEPTB;MkWuN|U{PiEQvF2= MXvTRW5ITVJ?
COLO-680N MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO5UVNKSzVyPUK1MlY{OjlizszN NE\0VJhUSU6JRWK=
KYSE-520 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX4TWM2OD1{NT62OFQh|ryP NYjROmdzW0GQR1XS
NB10 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XyZWlEPTB;Mk[uN|EyPyEQvF2= MoKxV2FPT0WU
NCI-H661 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ4LkS3NVMh|ryP NF\2fFJUSU6JRWK=
GMS-10 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnJfoFzUUN3ME2yOk45PjN6IN88US=> NHXrSZBUSU6JRWK=
NCI-H2122 MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjXTWM2OD1{Nj65PVk5KM7:TR?= NXH2bJdKW0GQR1XS
OVCAR-8 NE[2U5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TiRWlEPTB;MkeuNFY{QCEQvF2= NEPsZ|VUSU6JRWK=
DJM-1 NEfsRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzBXHRKSzVyPUK3MlE1PTRizszN M3nXVXNCVkeHUh?=
UACC-893 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXTTWM2OD1{Nz65PFc5KM7:TR?= MnvyV2FPT0WU
C8166 NWnqUW8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\QTWM2OD1{OD62PVM5KM7:TR?= NFfLXItUSU6JRWK=
NCI-H1693 M3vsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fpWWlEPTB;MkiuOlk4PSEQvF2= MYfTRW5ITVJ?
TYK-nu M2HZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\2TWM2OD1|MD6wN|Q2KM7:TR?= MnL5V2FPT0WU
SW1710 M1PkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TmW2lEPTB;M{CuNVI3KM7:TR?= MnG3V2FPT0WU
A375 NWDrOWs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnyXFhKSzVyPUOwMlMzPDNizszN M{HudXNCVkeHUh?=
HMV-II NXHrb3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTDXopnUUN3ME2zNU4{PTl{IN88US=> M3nSdnNCVkeHUh?=
NCI-H2087 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XyW2lEPTB;M{GuOlM2OiEQvF2= NY\kZo06W0GQR1XS
CAL-54 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTNzLkeyOFEh|ryP NWrnUHNMW0GQR1XS
HCC70 NXPMblhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y3eGlEPTB;M{KuNVM5PyEQvF2= MkXSV2FPT0WU
ES1 NHjVZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P1XWlEPTB;M{KuN|A3OiEQvF2= M1rFR3NCVkeHUh?=
NCI-H1355 M{DYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXwOWhKSzVyPUOzMlIxPCEQvF2= MVrTRW5ITVJ?
CFPAC-1 NHfkXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r1U2lEPTB;M{OuNlM{OiEQvF2= M3XKdXNCVkeHUh?=
MKN28 NV\ZRmxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rLN2lEPTB;M{OuN|gxQSEQvF2= NWD5V4RqW0GQR1XS
HDLM-2 NHHq[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTN|Lk[5N|Eh|ryP M2HsdHNCVkeHUh?=
PANC-10-05 M2Xqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC4dIxDUUN3ME2zOE4yODF2IN88US=> MYnTRW5ITVJ?
SAS Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnJeYhwUUN3ME2zOE41PTZ3IN88US=> NWf2ZYdHW0GQR1XS
HCC1395 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfzdHpKSzVyPUO0MlcyQDZizszN MkfRV2FPT0WU
8305C NWm2SopPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN3Lki0NVUh|ryP NIqxcm9USU6JRWK=
KM12 NXHWOpRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KxdGlEPTB;M{[uO|U1PyEQvF2= NHnRc3RUSU6JRWK=
SW1116 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoizTWM2OD1|Nz61PVkzKM7:TR?= M4TNOHNCVkeHUh?=
SK-MEL-1 M1flV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS5TWM2OD1|OD6zN|g6KM7:TR?= Mlv0V2FPT0WU
HCC2218 NWSxb5FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;MPWlEPTB;M{iuOlUyQSEQvF2= NVzCXW8xW0GQR1XS
T84 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjGWmVKSzVyPUO4Mlc1ODlizszN NF:xbJVUSU6JRWK=
ETK-1 NUi2bVJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTN7LkCyNkDPxE1? MYrTRW5ITVJ?
COLO-800 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHOTWM2OD1|OT6zPFY5KM7:TR?= NVy1[2NCW0GQR1XS
CAL-12T M3nyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:0VVh4UUN3ME2zPU42OjhzIN88US=> MYLTRW5ITVJ?
ACN M1LqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTRyLkS5NVEh|ryP MlPvV2FPT0WU
SJSA-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n6ZmlEPTB;NEGuNVU6PiEQvF2= MWnTRW5ITVJ?
PSN1 NUfVWmVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTlTWM2OD12MT6xO|Q6KM7:TR?= NFToNGlUSU6JRWK=
D-566MG M2LXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTRzLkKwPFYh|ryP MXTTRW5ITVJ?
EGI-1 NYHUUZJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjLWG1KSzVyPUSyMlQzQCEQvF2= NF;uZlBUSU6JRWK=
A204 NHKxdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDhelROUUN3ME20Nk43Ozh6IN88US=> MX3TRW5ITVJ?
Saos-2 M{TLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLhNYtKSzVyPUSyMlg{PjlizszN M2XTV3NCVkeHUh?=
SNU-C2B NGTKbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTR|Lk[4O|gh|ryP NH7ERW5USU6JRWK=
HLE M37kOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTiU2JGUUN3ME20OE4xQDV4IN88US=> NXPPUXZZW0GQR1XS
SW1463 NF7ZN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LNZWlEPTB;NESuPVk4OSEQvF2= Ml7sV2FPT0WU
DSH1 M{PGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPETWM2OD12NT6wNFM{KM7:TR?= NW\jbnNwW0GQR1XS
MCF7 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjIUWJKSzVyPUS1MlUxPTFizszN MnLTV2FPT0WU
K5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTR3Lkm0NFUh|ryP NVTxe3IxW0GQR1XS
NCI-H358 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;wbFc2UUN3ME20O{4zOTVizszN NHryPVRUSU6JRWK=
NCI-H2030 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfDTYw5UUN3ME20O{4zOzd2IN88US=> Mlj5V2FPT0WU
SW948 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XKdWlEPTB;NEeuOFY1KM7:TR?= NIPMfXFUSU6JRWK=
BALL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTR5Lk[xOlgh|ryP NYrienhYW0GQR1XS
TE-9 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTpRXJKSzVyPUS3Mlk2QDFizszN MUPTRW5ITVJ?
SK-N-FI M33Gd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL4TWM2OD12OD6wN|U5KM7:TR?= MULTRW5ITVJ?
KALS-1 NETWb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[zOmZKSzVyPUS4MlEzQDlizszN NWjp[YpqW0GQR1XS
HO-1-N-1 NWDOSpdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LCcGlEPTB;NEiuO|Q1PSEQvF2= MmC4V2FPT0WU
NCI-H2452 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TIbmlEPTB;NEmuNVE2OiEQvF2= NUntPWo{W0GQR1XS
OC-314 NHu1RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[yR2hMUUN3ME20PU43QDN2IN88US=> NILjZ2dUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+corn oil 7mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-263 (Navitoclax) | ABT-263 (Navitoclax) supplier | purchase ABT-263 (Navitoclax) | ABT-263 (Navitoclax) cost | ABT-263 (Navitoclax) manufacturer | order ABT-263 (Navitoclax) | ABT-263 (Navitoclax) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID